Stockscreener 앱 받기
15.31
0.07%
0.010
전일 마감가:
$15.30
열려 있는:
$15.3
하루 거래량:
150.26K
Relative Volume:
0.50
시가총액:
$366.87M
수익:
$47.26M
순이익/손실:
$-58.48M
주가수익비율:
-7.2905
EPS:
-2.1
순현금흐름:
$-40.45M
1주 성능:
+13.24%
1개월 성능:
+52.04%
6개월 성능:
+105.50%
1년 성능:
-24.02%
1일 변동 폭
$14.90
$15.67
1주일 범위
$13.38
$16.02
52주 변동 폭
$6.40
$33.13
Cvrx Inc Stock (CVRX) Company Profile
명칭
Cvrx Inc
전화
(763) 416-2850
주소
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
CVRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
15.31 | 366.87M | 47.26M | -58.48M | -40.45M | -2.10 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-11 | 재확인 | Lake Street | Buy |
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2024-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Lake Street | Buy |
| 2022-07-18 | 개시 | Craig Hallum | Buy |
| 2021-07-26 | 개시 | Canaccord Genuity | Buy |
| 2021-07-26 | 개시 | Piper Sandler | Overweight |
| 2021-07-26 | 개시 | William Blair | Outperform |
모두보기
Cvrx Inc 주식(CVRX)의 최신 뉴스
CVRx Insiders May Regret Not Buying More, Market Cap Hits US$377m - Simply Wall St
Cvrx (CVRX) Declined Due To Turbulence In The Direct Sales Team - MSN
(CVRX) Trading Report - Stock Traders Daily
Paul Verrastro Sells 1,430 Shares of CVRx, Inc. (NASDAQ:CVRX) Stock - MarketBeat
CVRx chief marketing officer Paul Verrastro sells $19,416 in stock By Investing.com - Investing.com Nigeria
CVRx chief marketing officer Paul Verrastro sells $19,416 in stock - Investing.com
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
CVRx to Present at Piper Sandler 36th Annual Healthcare Conference in December | CVRX Stock News - StockTitan
CVRx, Inc. (NASDAQ:CVRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
CVRx’s Barostim Gains New CPT Codes - MPO-mag
CVRx Inc (CVRX) Shares Down 6.46% on Nov 13 - GuruFocus.com
(CVRX) Long Term Investment Analysis - Stock Traders Daily
International Assets Investment Management LLC Makes New Investment in CVRx, Inc. (NASDAQ:CVRX) - MarketBeat
CVRx: Impressive Top-Line Growth Seems Priced In - Seeking Alpha
Cantor Fitzgerald Initiates Coverage of CVRx (CVRX) with Overweight Recommendation - MSN
CVRx (NASDAQ:CVRX) Stock Price Expected to Rise, Craig Hallum Analyst Says - MarketBeat
CVRx earns Medicare win for Barostim procedure - Mass Device
CVRx gains CMS payment classification for Barostim - Investing.com
CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025 - GlobeNewswire
CVRx, Inc. (NASDAQ:CVRX) Position Decreased by Emerald Advisers LLC - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Q3 2024 Earnings Call Transcript - MSN
FY2024 EPS Estimates for CVRx Lowered by Cantor Fitzgerald - MarketBeat
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report - Simply Wall St
CVRx, Inc. (NASDAQ:CVRX) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
How the (CVRX) price action is used to our Advantage - Stock Traders Daily
CVRx Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Canaccord lifts CVRx stock target, keeps buy rating on strong Q3 results By Investing.com - Investing.com South Africa
Canaccord lifts CVRx stock target, keeps buy rating on strong Q3 results - Investing.com
Earnings call: CVRx reports robust Q3 growth, eyes future reimbursement wins - Investing.com India
CVRx (NASDAQ:CVRX) Given New $15.00 Price Target at Lake Street Capital - MarketBeat
CVRx (NASDAQ:CVRX) Given "Overweight" Rating at Piper Sandler - MarketBeat
CVRx Reports Strong Revenue Growth in Q3 2024 - TipRanks
CVRx earnings missed by $0.10, revenue topped estimates - Investing.com Canada
CVRx: Q3 Earnings Snapshot - The Advocate
CVRx Reports Third Quarter 2024 Financial and Operating Results - GlobeNewswire
CVRx Inc Q3 2024 Earnings: Revenue Hits $13.4M, EPS at -$0.57, S - GuruFocus.com
CVRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Earnings To Watch: CVRx Inc (CVRX) Reports Q3 2024 Result - GuruFocus.com
CVRx (CVRX) Price Target Increased by 10.54% to 33.15 - MSN
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles By Investing.com - Investing.com South Africa
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles - Investing.com India
CVRx (NASDAQ:CVRX) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Cvrx Inc (CVRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cvrx Inc 주식 (CVRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Nov 19 '24 |
Sale |
13.58 |
1,430 |
19,417 |
1,875 |
0.65%
자본화:
|
볼륨(24시간):